Medtronic (NYSE:MDT) and UnitedHealthcare (NYSE:UNH) today touted first-year results from a 6,000-person analysis designed to compare hospital admission rates between people with diabetes using insulin pumps and people controlling their diabetes with multiple daily injections of insulin.
The study included people using Medtronic’s MiniMed 630G system, as well as previous iterations of the medtech giant’s insulin pumps.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic touts one-year data from insulin pump study appeared first on MassDevice.